|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q1 FY2021
As of Mar 31, 2021
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Accounts receivables | ||||||||||||||||||||
| Discount on convertible notes | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Related party loan | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net of accumulated depreciation and amortization | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Total non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity/(Deficit) | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Accounts payables | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Convertible notes | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Accrued and other liabilities | ||||||||||||||||||||
| Long-term debt – current position | ||||||||||||||||||||
| Line of credit | ||||||||||||||||||||
| Related party loan | ||||||||||||||||||||
| Related party loan | ||||||||||||||||||||
| Income tax liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt – non-current position | ||||||||||||||||||||
| Total non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Common stock Authorized: $0.001 par value, 290,000,000 shares authorized Issued and outstanding: 26,711,000 and 73,590,730, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Preference Stock Authorized: $0.001 par value, 10,000,000 shares authorized Issued and outstanding: 2,600,000 and 0 Nil, respectively | ||||||||||||||||||||
| Adjustments to equity to reflect retroactive application of reverse acquisition of accounting | ||||||||||||||||||||
| Accumulated losses | ||||||||||||||||||||
| Foreign currency translation differences | ||||||||||||||||||||
| Total stockholders’ surplus/(deficit) | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
